ReShape Lifesciences Inc
NASDAQ:RSLS

Watchlist Manager
ReShape Lifesciences Inc Logo
ReShape Lifesciences Inc
NASDAQ:RSLS
Watchlist
Price: 3.92 USD 22.5% Market Closed
Market Cap: $290.2m

Wall St Price Targets

RSLS Price Targets Summary
ReShape Lifesciences Inc

There are no price targets for RSLS.
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
ReShape Lifesciences Inc Competitors:
Price Targets
558
LK Technology Holdings Ltd
113% Upside
CAMT
Camtek Ltd
40% Upside
LEG
Leggett & Platt Inc
11% Upside

Revenue
Forecast

8% / Year
Past Growth
53% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
8% / Year
Past Growth
53% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 9 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 1 year is 53%.

Gross Profit
Forecast

14% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
14% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for ReShape Lifesciences Inc

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Pre-Tax Income Forecast
is not available for ReShape Lifesciences Inc

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-100%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-100%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is RSLS's stock price target?
Not Available

RSLS does not have any price targets made by Wall Street professionals.

What is the Revenue forecast for ReShape Lifesciences Inc?
Projected CAGR
53%

Over the last 9 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 1 year is 53%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett